netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Alternative Treatment for Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that damages blood vessels in the light-sensitive retina in the back of the eye. Lucentis is used to treat wet macular degeneration as well as diabetic macula edema. The study found the treatment no less effective than the laser therapy which currently is the standard treatment for PDR.

Read the press release.

Read the study.

In a RPB-supported commentary, Timothy W. Olsen, MD, notes that "this important study [...] represents a major step forward for patients with PDR by providing the ophthalmologists who manage their retinal disease with new options." But he adds a cautionary note. 

Read the commentary.

 

Related News: Diabetic Retinopathy, Top Story

New Findings on Blood Vessel Regulation

A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.

Read More

 

RPB-SUPPORTED RESEARCHERS INTEGRAL TO NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 

EMERGING VISION SCIENTISTS EDUCATE, THANK CONGRESS FOR RESEARCH APPROPRIATIONS

(NAEVR) held its Fourth Annual Emerging Vision Scientists (EVS) Day on Capitol Hill and twenty early-stage investigators participated.

Read More

 

RPB AND LCIF TO CONTINUE LOW VISION RESEARCH AWARD PARTNERSHIP

Research to Prevent Blindness (RPB) and Lions Clubs International Foundation (LCIF) announced today that they will continue their partnership in the RPB/LCIF Low Vision Research Award.

Read More

 

RPB researchers honored with 2018 António Champalimaud Vision Award

Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research

Read More

 

IN THE FUTURE, ALZHEIMER’S MAY BE PREDICTED DURING EYE EXAMS

RPB-funded researchers at Washington University School of Medicine in St. Louis (WUSTL) have found a correlation in 30 older patients between retina thinning and elevated levels of tau and amyloid proteins that are the hallmark of Alzheimer’s disease.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.